An observational study presented by the University of Pennsylvania Perelman School of Medicine’s Elizabeth McDonald, MD, PhD at the 2026 ASCO Annual Meeting (Abstract 10506) suggests a connection between GLP-1 medications and lower breast cancer risk. The findings are summarized in a press release.
